亚盛医药点评:多项临床亮相ASCO和EHA大会,优秀数据助力管线商业化【东吴医药朱国广团队】

国广有话说
Jun 20

点击蓝字 关注我们投资要点投资要点事件:2025年6月16日,亚盛医药核心产品奥雷巴替尼关于费城染色体阳性(Ph+)急性淋巴细胞白血病(ALL)的临床数据在EHA年会上公布,其与多种药物的联合治疗方案数据显示出奥雷巴替尼有望为Ph+ ALL进一步改善患者长期预后。而在此之前的5月30日,亚盛医药连续第八年两项ASCO年会,并带来了APG-2575联合疗法在初治或既往接受过维奈克拉治疗的髓系恶性肿瘤...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10